Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01748175 · ClinicalTrials.gov registry record
Implications and Stability of Clinical and Molecular Phenotypes of Severe Asthma
A clinical trial, sponsored by Sally E. Wenzel MD.
- Completed
- Registry status
- 715
- Enrollment target
NCT01748175 is a clinical trial that has completed, run by Sally E. Wenzel MD. The registered enrollment target is 715 participants.
The verdict
NCT01748175 has completed, sponsored by Sally E. Wenzel MD.
- COMPLETED
- Registry status
- 715 participants
- Enrollment target
Study Summary
The Severe Asthma Research Program III is an NIH cooperative agreement involving 7 clinical centers that encompass a multidisciplinary partnerships between asthma clinician-scientists and scientists with expertise in immunology, pulmonary physiology, molecular genetics, molecular phenotyping, imaging, and bioinformatics. These clinical centers will jointly recruit volunteers with asthma for an observational longitudinal follow-up study. However, centers will also conduct specific mechanistic research projects at each participating institution. The University of Pittsburgh's SARP III study will determine the molecular and clinical stability of asthma phenotypes over time.
Interventions
- DRUG Triamcinolone Acetonide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 715 participants |
| Start Date | 2013-01 |
| Est. Completion | 2022-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01748175
The ClinicalTrials.gov registry entry for NCT01748175 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 715 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sally E. Wenzel MD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Triamcinolone Acetonide is the first listed.
NCT01748175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01748175 about?
NCT01748175 is a clinical study titled "Implications and Stability of Clinical and Molecular Phenotypes of Severe Asthma". The Severe Asthma Research Program III is an NIH cooperative agreement involving 7 clinical centers that encompass a multidisciplinary partnerships between asthma clinician-scientists and scientists with expertise in immunology, pulmonary physiology, molecular genetics, molecular phenotyping, imagin...
What is the current status of trial NCT01748175?
This trial is currently completed. The enrollment target is 715 participants. The study started on 2013-01. Estimated completion is 2022-01.
What interventions are being tested in trial NCT01748175?
The interventions under investigation include: Triamcinolone Acetonide (DRUG).
Who is sponsoring clinical trial NCT01748175?
This trial is sponsored by Sally E. Wenzel MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.